H5N1 News and Research

Latest H5N1 News and Research

U.S. journal Science publishes controversial H5N1 research

The U.S. journal Science on Thursday published the results of a controversial study in which researchers at the Erasmus Medical Center in the Netherlands "identified five mutations apparently necessary to make the [H5N1] bird flu virus spread easily among ferrets, which catch the same flus that humans do," the New York Times reports (McNeil, 6/21).

22 Jun 2012

VaxInnate commences VAX161 Phase I trial in pandemic avian influenza

VaxInnate Corporation today announced that enrollment has commenced in a Phase I clinical trial to evaluate VAX161, its novel H5 vaccine candidate in development for the prevention of pandemic avian influenza or bird flu. VaxInnate is a biotechnology firm pioneering breakthrough technology for developing novel vaccines.

13 Jun 2012

WHO hopes to host second meeting on issues related to 'dual-use' research

"The World Health Organization (WHO) hopes to hold a meeting late this fall to discuss 'dual-use' research issues raised in the controversy over publication of two studies involving lab-modified H5N1 viruses with increased transmissibility, a WHO official said," CIDRAP News reports.

1 Jun 2012

Single test developed that detects all known strains of H5N1

The close collaboration between scientists from the Experimental Therapeutics Centre (ETC) under the Agency for Science and Technology Research (A*STAR) and clinicians from Tan Tock Seng Hospital (TTSH) has enabled the successful development of the most comprehensive and rapid H5N1 bird flu test kit available to date.

29 May 2012

Researcher restructures innovative virus-tracking software

A biomedical informatics researcher who tracks dangerous viruses as they spread around the globe has restructured his innovative tracking software to promote even wider use of the program around the world.

23 May 2012

Inovio SynCon avian influenza vaccine demonstrates broad coverage

Inovio Pharmaceuticals, Inc. announced today that its SynCon avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial - a distinct clinical achievement on Inovio's path to develop universal influenza vaccines.

17 May 2012

Sinovac first quarter sales increase 30.3% to $6.0M

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012.

15 May 2012

Inovio first quarter total revenue decreases to $1.7 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2012.

10 May 2012

Researchers discover potential way to develop universal flu vaccines

University of British Columbia researchers have found a potential way to develop universal flu vaccines and eliminate the need for seasonal flu vaccinations.

8 May 2012

NIH responds to criticism over handling of controversial bird flu studies

In a letter dated April 25, Amy Patterson, associate director for science policy in the office of the director of the National Institutes of Health, "has refuted criticism of the way a meeting held to allow a biosecurity advisory group to review controversial bird flu studies was handled," denying "the agenda was crafted to achieve a predetermined outcome," the Canadian Press/Winnipeg Free Press writes.

7 May 2012

Nature publishes first of two controversial studies on H5N1 avian flu

"In a long-awaited study that helped prompt a contentious debate over the wisdom of conducting research that has the potential to help as well as harm, scientists reported Wednesday that they had engineered a mutant strain of [H5N1] bird flu that can spread easily between ferrets -- a laboratory animal that responds to flu viruses much as people do," the Los Angeles Times (Brown, 5/3).

4 May 2012

One of the controversial avian flu studies published in full finally

After endless debates and controversies on whether two studies that demonstrated how bird flu, also known as avian H5N1 influenza, or avian flu, should be published, one of them has appeared in the latest issue of the journal Nature in its entirety. The two studies aimed for publication in journals Nature and Science show how the bird flu virus could become transmissible from mammal-to-mammal; as humans are mammals, the same would apply to humans.

4 May 2012

U.S. to ask university officials how best to implement new DURC policy

"The U.S. government will soon be asking university officials to comment on how best to implement recently released dual use research rules at the university level," according to Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases (NIAID), who spoke Monday at a workshop sponsored by the National Academies in Washington, ScienceInsider reports.

3 May 2012

Flu paper publication amidst threats of bioterrorism raises need for better rules of censorship

According to the editor of the scientific journal Nature, Dr Philip Campbell current procedures to assess and censor medical research potentially of use to terrorists need to be improved. He was speaking about the recent controversy regarding the bird flu virus H5N1 study. The study was initially stopped from publication fearing risk of bioterrorism. He was speaking to BBC News.

2 May 2012

'Mandatory oversight' of potentially dangerous biological research will be necessary

"In the sobering annals of disaster prevention, genetic manipulation of the H5N1 influenza virus is looming as a seminal case," John Steinbruner, director of the Center for International Security Studies at the University of Maryland, writes in an opinion piece in The Hill's "Congress Blog," noting that two "laboratory experiments have rendered the highly virulent avian strain transmissible among ferrets, strongly suggesting that it would be transmissible among humans as well."

2 May 2012

Dutch government grants export license allowing publication of controversial H5N1 study

"The Dutch government has agreed to grant an export license to allow Ron Fouchier, a virologist at the Erasmus Medical University in Rotterdam, to publish his work on H5N1 avian influenza in Science," Nature's "News Blog" reports (Owens, 4/27). "

30 Apr 2012

Senate committee questions federal officials about dual-use research of concern procedures

"Spurred by events surrounding two controversial H5N1 transmission studies, a U.S. Senate committee [on Thursday] questioned federal officials whose agencies have a stake in dual-use research of concern (DURC) about the procedures they use to spot possible bioterror threats," CIDRAP News reports.

27 Apr 2012

Funders should follow lead of U.S. in creating policies for scientific research oversight

"The controversy over the research into the genetic modification of the H5N1 flu virus, finally approved for publication, should offer a reminder of the importance of debate" over dual-use technology, a Nature editorial states.

27 Apr 2012

U.S. government must be prepared to handle dual use research of concern

"This week, a Senate panel is investigating biological security in the wake of" controversial "potentially dangerous research" on H5N1 avian influenza, "with good reason," Rep. Jim Sensenbrenner (R-Wisc.) writes in a Washington Times opinion piece.

26 Apr 2012

Rep. Sensenbrenner sends second letter inquiring about U.S. government's review of controversial H5N1 studies

"A senior Republican in the U.S. House of Representatives is asking more questions about how the U.S. government reviewed two controversial H5N1 avian influenza studies, and how it wrote a new policy for reviewing taxpayer-funded studies that might be used for good and evil," ScienceInsider reports.

25 Apr 2012